PostEra Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PostEra Inc. - overview
Established
2019
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2019 by its CEO, Aaron Morris, CTO Matt Robinson, and CSO Alpha Lee, PostEra Inc. is a biotechnology company that uses machine learning for preclinical drug discovery. In January 2022, PostEra Inc. raised USD 24 million in series A financing led by Clermont Group, with Breyer Capital, I2BF, and LifeForce Capital.
PostEra Inc. offers medicinal chemistry powered by machine learning and reduces their clients' cycle times. The company has developed COVID oral antiviral candidates via the COVID Moonshot, the advancement of several drug discovery efforts with biopharma partners, and the launch of Manifold as an industry synthesis platform. PostEra Inc.
will use the series A funding to advance a series of partnered drug discovery programs, initiate its own internal drug discovery program, and further develop its medicinal chemistry platform.
Current Investors
Y Combinator, ACE & Company, Pioneer Fund
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.postera.ai
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.